Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;6(3):189-98.
doi: 10.1177/1756285613481083.

Efficacy and safety of rufinamide in pediatric epilepsy

David T Hsieh  1 , Elizabeth A Thiele
Affiliations

Efficacy and safety of rufinamide in pediatric epilepsy

David T Hsieh et al. Ther Adv Neurol Disord. 2013 May.

Abstract

Rufinamide is a novel anticonvulsant medication approved by the US Food and Drug Administration (FDA) in 2008 for the treatment of seizures associated with Lennox-Gastaut syndrome in patients 4 years of age and older, based upon clinical trials demonstrating clinical efficacy and tolerability. Rufinamide is especially effective for tonic-atonic seizures in Lennox-Gastaut syndrome, but is subsequently proving to be safe and effective in clinical practice for a broad patient population with refractory epilepsy. Although further research and clinical experience is needed, rufinamide holds the promise to positively impact the care of children with epilepsy. In this review, we review the use of rufinamide in pediatric epilepsy, with a focus on efficacy and safety.

Keywords: Lennox–Gastaut syndrome; anticonvulsants; epilepsy; rufinamide.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare that there are no conflicts of interest.

Similar articles

See all similar articles

Cited by

References

    1. Aldenkamp A., Alpherts W. (2006) The effect of the new antiepileptic drug rufinamide on cognitive functions. Epilepsia 47: 1153–1159 - PubMed
    1. Berg A., Levy S., Testa F., D’Souza R. (2009) Remission of epilepsy after 2 drug failures in children: a prospective study. Ann Neurol 65: 510–519 - PMC - PubMed
    1. Biton V., Krauss G., Vasquez-Santana B., Bibbiani F., Mann A., Perdomo C., et al. (2011) A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures. Epilepsia 52: 234–242 - PubMed
    1. Brodie M., Barry S., Bamagous G., Norrie J., Kwan P. (2012) Patterns of treatment response in newly diagnosed epilepsy. Neurology 78: 1548–1554 - PMC - PubMed
    1. Brodie M., Rosenfeld W., Vazquez B., Sachdeo R., Perdomo C., Mann A., et al. (2009) Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 50: 1899–1909 - PubMed

LinkOut - more resources